Literature DB >> 21508093

The oligomeric state of thyroid receptor regulates hormone binding kinetics.

Suzana T Cunha Lima1, Edson D Rodrigues.   

Abstract

We previously reported that mutations in the thyroid hormone receptor (TR) surface that mediates dimer and heterodimer formation do not alter affinity for cognate hormone (triiodothyronine (T(3))) yet dramatically enhance T(3) association and dissociation rates. This study aimed to show that TR oligomeric state influences binding and dissociation kinetics. We performed binding assays using marked hormone ((125)I-T(3)) and TRs expressed and purified by different methods. We find that T(3) associates with TRs with biphasic kinetics in solution; a rapid step (half-life ±0.1 h) followed by a slower second step (half-life ±5 h) and that purification of monomers suggests that biphasic kinetics are due to the presence of monomers and dimers in our preparations. In support of this idea, incubation of TR ligand binding domain monomers with corepressor peptide induces dimer formation and decreases association rates and T(3) binds to, and dissociates from, a TRβ mutant that only forms dimers (TRβD355R) with slow single-phase kinetics. In addition, heterodimer formation with retinoid X receptors also influences ligand binding kinetics. Together, these results suggest that the dimer/heterodimer surface is allosterically coupled to the hormone binding pocket and that different interactions at this surface exert different effects on ligand binding that may be relevant for TR actions in the cell.
© 2011 Society for Endocrinology

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21508093     DOI: 10.1530/JOE-11-0019

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  1 in total

1.  Site-specific basicities regulate molecular recognition in receptor binding: in silico docking of thyroid hormones.

Authors:  Gergő Tóth; Ferenc Baska; András Schretner; Akos Rácz; Béla Noszál
Journal:  Eur Biophys J       Date:  2013-08-02       Impact factor: 1.733

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.